Abstract
Understanding protein-ligand interactions is a critical step in rational drug design/virtual ligand screening. In this work we applied the AMMOS_ProtLig software for post-docking optimization of estrogen receptor alpha complexes generated after virtual ligand screening protocol. Using MOE software we identified the ligand-receptor interactions in the optimized complexes at different levels of protein flexibility and compared them to the experimentally observed interactions. We analyzed in details the binding sites of three X-ray complexes of the same receptor and identified the key residues for the protein-ligand interactions. The complexes were further processed with AMMOS_ProtLig and the interactions in the predicted poses were compared to those observed in the X-ray structures. The effect of employing different levels of flexibility was analyzed. The results confirmed the AMMOS_ProtLig applicability as a helpful postdocking optimization tool for virtual ligand screening of estrogen receptors.
Keywords: AMMOS, binding site, estrogen receptor, in silico screening, protein flexibility, protein-ligand interactions, ligand, screening, X-ray, Complexes
Current Computer-Aided Drug Design
Title:Post-Docking Optimization and Analysis of Protein-Ligand Interactions of Estrogen Receptor Alpha using AMMOS Software
Volume: 9 Issue: 1
Author(s): Tania Pencheva, Dessislava Jereva, Maria A. Miteva and Ilza Pajeva
Affiliation:
Keywords: AMMOS, binding site, estrogen receptor, in silico screening, protein flexibility, protein-ligand interactions, ligand, screening, X-ray, Complexes
Abstract: Understanding protein-ligand interactions is a critical step in rational drug design/virtual ligand screening. In this work we applied the AMMOS_ProtLig software for post-docking optimization of estrogen receptor alpha complexes generated after virtual ligand screening protocol. Using MOE software we identified the ligand-receptor interactions in the optimized complexes at different levels of protein flexibility and compared them to the experimentally observed interactions. We analyzed in details the binding sites of three X-ray complexes of the same receptor and identified the key residues for the protein-ligand interactions. The complexes were further processed with AMMOS_ProtLig and the interactions in the predicted poses were compared to those observed in the X-ray structures. The effect of employing different levels of flexibility was analyzed. The results confirmed the AMMOS_ProtLig applicability as a helpful postdocking optimization tool for virtual ligand screening of estrogen receptors.
Export Options
About this article
Cite this article as:
Pencheva Tania, Jereva Dessislava, A. Miteva Maria and Pajeva Ilza, Post-Docking Optimization and Analysis of Protein-Ligand Interactions of Estrogen Receptor Alpha using AMMOS Software, Current Computer-Aided Drug Design 2013; 9 (1) . https://dx.doi.org/10.2174/1573409911309010008
DOI https://dx.doi.org/10.2174/1573409911309010008 |
Print ISSN 1573-4099 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6697 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Management of Neonatal Soft-tissue Sarcomas and Benign Tumors with Local Aggressiveness
Current Pediatric Reviews Folate-Linked Lipid-Based Nanoparticle for Targeted Gene Delivery
Current Drug Delivery CORAL: Classification Model for Predictions of Anti-Sarcoma Activity
Current Topics in Medicinal Chemistry Targeting Myc in Pediatric Malignancies of the Central and Peripheral Nervous System
Current Cancer Drug Targets A Unique Mechanism of Chaperone Action: Heme Regulation of Hap1 Activity Involves Separate Control of Repression and Activation
Protein & Peptide Letters Topoisomerase II Inhibitors and Poisons, and the Influence of Cell Cycle Checkpoints
Current Medicinal Chemistry Structure of Multidrug-Resistance Proteins of the ATP-Binding Cassette (ABC) Superfamily
Current Medicinal Chemistry - Anti-Cancer Agents pH-Sensitive PEGylated Liposomes Functionalized With a Fibronectin-Mimetic Peptide Show Enhanced Intracellular Delivery to Colon Cancer Cells
Current Pharmaceutical Biotechnology Identification of Sets of Cytoskeletal Related and Adhesion-related Coding Region Mutations in the TCGA Melanoma Dataset that Correlate with a Negative Outcome
Current Genomics Recent Progress in the Development of Histone Deacetylase Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry Nanosponges Encapsulated Phytochemicals for Targeting Cancer: A Review
Current Drug Targets Potential Therapeutic Applications of miRNA-Based Technology in Hematological Malignancies
Current Pharmaceutical Design Tyrosine Kinases as Targets for Anti-Inflammatory Therapy
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Viral Vector-Mediated Gene Therapy for Hemophilia
Current Gene Therapy Phosphoproteomics: Challenges and Opportunities
Current Proteomics CARD Proteins as Therapeutic Targets in Cancer
Current Drug Targets Emerging Role of Stromal Fibroblasts in Epithelial Cancer
Current Signal Transduction Therapy AKT: A Potential Target for Thyroid Cancer Therapy
Current Drug Targets - Immune, Endocrine & Metabolic Disorders The Synthesis and Antiviral Properties of Acyclic Nucleoside Analogues with a Phosphonomethoxy Fragment in the Side Chain
Current Medicinal Chemistry Pixuvri<sup>®</sup> (Pixantrone Dimaleate, BBR 2778): From Lab to Market
Current Organic Chemistry